New tiny CRISPR molecule reported
A report describes a newly identified, smaller CRISPR molecule that could improve therapeutic genome editing, and it notes support from NIH’s National Institute of General Medical Sciences. (bioengineer.org) The coverage presents the work as early‑stage research with potential implications for delivery and specificity. (bioengineer.org)
Gene editing works by sending a protein and a guide molecule to a chosen spot in DNA, then cutting there so the cell repairs it. The new report centers on a much smaller cutter, called Al3Cas12f, that may be easier to deliver inside the body. (nih.gov) The team from the University of Texas at Austin and Metagenomi Therapeutics reported the work on April 13, 2026, in *Nature Structural & Molecular Biology*. They compared several Cas12f enzymes and focused on one natural version, Al3Cas12f. (nature.com) Size is the bottleneck here. Common CRISPR proteins are often too large for adeno-associated virus, a widely used delivery vehicle in gene therapy, while UT said Al3Cas12f is small enough to fit. (utexas.edu) Researchers used structural imaging and machine learning to study why this small enzyme worked better than related ones. They found Al3Cas12f forms a more stable complex with its guide RNA and target DNA than other enzymes of similar size. (nature.com) They then engineered a version called Al3Cas12f RKK. The National Institutes of Health said editing efficiency rose from under 10% to more than 80% across tested targets, and reached 90% at one commonly edited site in human cells. (nih.gov) Those tests were done in cultured human cells, including a leukemia-derived cell line, not in patients. The paper says the result is an AAV-compatible editor that “seems to expand” the feasibility of low-dose therapeutic editing, which is still a step short of showing it works in animals or people. (nature.com) That distinction matters because the first approved CRISPR therapy, Casgevy, edits blood stem cells outside the body and returns them to the patient. Reviews of the field say in-body editing still faces delivery limits, dose constraints and safety questions, especially when larger editors must be packed into small viral carriers. (nature.com 1) (nature.com 2) Compact editors are already a crowded research lane. Papers published in 2025 described improved Cas12f1 systems and engineered IscB-based miniature editors, both aimed at making gene editing small enough for in-body delivery. (nature.com 1) (nature.com 2) The new study adds one more candidate to that race, with NIH saying the next step is to package Al3Cas12f into adeno-associated virus and test how it performs. The project was supported in part by the National Institute of General Medical Sciences through grant R35GM138348. (nih.gov)
